Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Study sponsor: Corcept Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-03-16Actual
Enrollment · participants178Actual
Source updated2025-10-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.